We recently published 12 Latest Stocks on Jim Cramer’s Radar . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Pfizer not only beat expectations last quarter, but also boosted its guidance.

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Shares of Pfizer Inc. rose 4.59% to $25.51 Tuesday, on what proved to be an all-around favorable trading session for the ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Pfizer Inc. (NYSE: PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating ...

Pfizer is a cheap stock by most metrics. It trades at a price-to-earnings multiple of only 13, while the S&P 500 average is ...

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing ...

There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be ...

Pfizer Inc's (NYSE: PFE) short interest as a percent of float has risen 8.25% since its last report. According to exchange ...

Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...